Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 16/20 | 0.79 |
| ▸ | MAP4K2 | Q12851 | 16/20 | 0.79 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 4/20 | 0.65 |
| ▸ | BMX | P51813 | 4/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | FES | P07332 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.65 |
| ▸ | FLT1 | P17948 | 1/20 | 0.65 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.65 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.65 |
| ▸ | TEK | Q02763 | 1/20 | 0.65 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26456798 | 0.91 | TNK2 (0.77) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL14183086 | 0.90 | TNK2 (0.65) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3130033 | 0.89 | TNK2 (0.70) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3139207 | 0.89 | TNK2 (0.78) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3135215 | 0.88 | TNK2 (1.00) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL29468185 | 0.88 | TNK2 (1.00) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3136742 | 0.88 | TNK2 (0.68) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3143790 | 0.87 | TNK2 (0.69) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3139743 | 0.86 | TNK2 (0.67) | TNK2MAP4K2MAPK3ABL1BMX | |
| SCHEMBL3140753 | 0.86 | TNK2 (0.69) | TNK2MAP4K2MAPK3ABL1BMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | claimed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | claimed |
| CN-1860118-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-08 | — | — | CN | claimed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | TNK2 1638/4885MAP4K2 1112/4885MAPK3 1065/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | TNK2 1638/4885MAP4K2 1112/4885MAPK3 1065/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | TNK2 1638/4885MAP4K2 1112/4885MAPK3 1065/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | TNK2 1638/4885MAP4K2 1112/4885MAPK3 1065/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | TNK2 203/4885MAP4K2 37/4885MAPK3 136/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | TNK2 203/4885MAP4K2 37/4885MAPK3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.